{"entity":{"id":"paper-capivasertib-breast-hr-positive-breast-2022","kind":"paper","name":"\"The emerging role of capivasertib in breast cancer\"","aka":[],"tldr":"Review on Capivasertib in HR-positive / HER2-negative breast cancer, in The Breast (2022), one of the most cited Europe PMC records with Capivasertib in its title.","summary":"Over 50% of breast tumors harbor alterations in one or more genes of the phosphatidylinositol 3-kinase (PI3K) pathway including PIK3CA mutations (31%), PTEN loss (34%), PTEN mutations (5%) and AKT1 mutations (3%). While PI3K and mTOR inhibitors are already approved in advanced breast cancer, AKT inhibitors have been recently developed as a new therapeutic approach. Capivasertib (AZD5363) is a novel, selective ATP-competitive pan-AKT kinase inhibitor that exerts similar activity against the three AKT isoforms, AKT1, AKT2, and AKT3. Preclinical studies demonstrated efficacy of capivasertib in breast cancer cell lines as a single agent or in combination with anti-HER2 agents and endocrine treatment, especially in tumors with PIK3CA or MTOR alterations. Phase I/II studies demonstrated greater efficacy when capivasertib was co-administered with paclitaxel, fulvestrant in hormone receptor (HR)-positive, HER2-negative breast cancer or olaparib. The recommended phase II dose of capivasertib as monotherapy was 480 mg bid on a 4-days-on, 3-days-off dosing schedule. Toxicity profile proved to be manageable with hyperglycemia (20-24%), diarrhea (14-17%) and maculopapular rash (11-16%) being the most common grade ≥3 adverse events. Ongoing Phase III trials of capivasertib in combination with fulvestrant (CAPItello-291), CDK4/6 inhibitor palbociclib (CAPItello-292) and paclitaxel (CAPItello- 290) will better clarify the therapeutic role of capivasertib in breast cancer.\n\nIndexed on Europe PMC as PubMed record 35398754 (DOI 10.1016/j.breast.2022.03.018). Its title names Capivasertib and its text names HR-positive / HER2-negative breast cancer; PubMed types it as a review (review-article, Review). It was matched automatically to the idea \"Molecular-progression switching beyond ESR1\" and no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Breast 2022","url":"https://doi.org/10.1016/j.breast.2022.03.018"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/35398754/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/35398754"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["the-breast"],"dependsOn":[],"notes":[],"journal":"The Breast","year":2022,"doi":"10.1016/j.breast.2022.03.018","pmid":"35398754","authors":"Andrikopoulou A, Chatzinikolaou S, Panourgias E, et al.","paperType":"review","findings":[],"whatItMeans":"One of the most cited reviews Europe PMC returns for Capivasertib in HR-positive / HER2-negative breast cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.","caveats":["Matched by Capivasertib in the title and HR-positive / HER2-negative breast cancer in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.","A review summarises other studies; the primary reports it cites are the evidence."]},"route":"/key-papers/paper-capivasertib-breast-hr-positive-breast-2022/","neighbours":{"journal":[{"id":"the-breast","kind":"journal","name":"The Breast","route":"/journals/the-breast/"}],"idea":[{"id":"idea-ctdna-switch-generalised","kind":"idea","name":"Molecular-progression switching beyond ESR1","route":"/ideas/idea-ctdna-switch-generalised/"}]}}